Search Dental Tribune

Interview: “This system is unique”

mininavident CEO Frank Berlinghoff (Photograph: Daniel Zimmermann, DTI)

Fri. 24. March 2017

save

Founded by facial surgeons four years ago, Swiss firm mininavident is currently presenting its real-time navigation system for implantologists at IDS. Dental Tribune Online had the opportunity to speak with CEO Frank Berlinghoff about the product and the benefits it offers to dentists.

Dental Tribune Online: Mr Berlinghoff, could you please explain the benefits of your navigation system?
Frank Berlinghoff: Our system provides a real-time view of the treatment situation during implantation. The dentist therefore effectively has a real-time radiographic image on which he or she can see the drill, the patient’s anatomy and the implant plan simultaneously. Another advantage is that the drilled holes are recorded, so that they can be compared with those on the plan. This is useful in subsequent prosthetic restorations.

This system is unique in that the dentist can practically look inside the patient during surgery and view all of the bone structures and other anatomical features. It even issues a warning if the surgeon comes too close to a nerve canal.

What have dentists said about the device?
We have already undertaken a range of usability tests on the prototypes, of course, both with experienced and less experienced implantologists. They have all said that such a system is useful. Of course, there is something of a learning curve, because they must first become used to the attachment on the handpiece and the marker in the patient’s mouth. Nevertheless, we have received a great deal of very promising feedback. On the first day of the show already, we held talks with a range of dealers and a number of implantologists. Many regard the miniaturisation in particular as a major advancement.

You are currently still presenting a pre-production model. When will the device be launched?
We expect to receive the CE marking for the product in the coming months. The final launch is scheduled for the fourth quarter of this year. We will initially focus on the German-speaking and European market, which is mainly to do with the partners and distribution partners with whom we currently collaborate.

In addition, we have already held talks with potential partners in the US, where we hope to receive US Food and Drug Administration approval soon. We have also already established contacts with partners from India, China and Brazil, where implantology is currently showing strong growth.

To post a reply please login or register
advertisement
advertisement